The antiserum was produced against synthesized peptide derived from human ERK8 around the phosphorylation site of Thr175 and Tyr177. AA range:141-190

This antibody detects endogenous levels of Erk8 when phosphorylated at Thr175 or Tyr177, and dually phosphorylated at two sites.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):VtEyVA

MAPK15

Mitogen-activated protein kinase 15

MAPK15 ;
ERK7 ;
ERK8 ;
Mitogen-activated protein kinase 15 ;
MAP kinase 15 ;
MAPK 15 ;
Extracellular signal-regulated kinase 7 ;
ERK-7 ;
Extracellular signal-regulated kinase 8 ;
ERK-8

catalytic activity:ATP + a protein = ADP + a phosphoprotein. ,domain:The N-terminal region (1-20) is the minimal region necessary for ubiquitination and further proteosomal degradation. ,domain:The TXY motif contains the threonine and tyrosine residues whose phosphorylation activates the MAP kinases. ,enzyme regulation:Activated by threonine and tyrosine phosphorylation. Inhibited by dual specificity phosphatases , such as DUSP1. ,function:In vitro , phosphorylates MBP. ,PTM:Dually phosphorylated on Thr-175 and Tyr-177 , which activates the enzyme. Autophosphorylated on threonine and tyrosine residues in vitro. ,PTM:Ubiquitinated. Ubiquitination may allow its tight kinase activity regulation and rapid turnover. May be ubiquitinated by a SCF E3 ligase. ,similarity:Belongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. MAP kinase subfamily. ,similarity:Contains 1 protein kinase domain. ,subunit:Interacts with CSK/c-Src , ABL1 , RET and TGFB1I1. ,tissue specificity:Widely expressed with a maximal expression in lung and kidney. ,

Catalytic activity:ATP + a protein = ADP + a phosphoprotein. ,Domain:The N-terminal region (1-20) is the minimal region necessary for ubiquitination and further proteosomal degradation. ,Domain:The TXY motif contains the threonine and tyrosine residues whose phosphorylation activates the MAP kinases. ,enzyme regulation:Activated by threonine and tyrosine phosphorylation. Inhibited by dual specificity phosphatases , such as DUSP1. ,Function:In vitro , phosphorylates MBP. ,PTM:Dually phosphorylated on Thr-175 and Tyr-177 , which activates the enzyme. Autophosphorylated on threonine and tyrosine residues in vitro. ,PTM:Ubiquitinated. Ubiquitination may allow its tight kinase activity regulation and rapid turnover. May be ubiquitinated by a SCF E3 ligase. ,similarity:Belongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. MAP kinase subfamily. ,similarity:Contains 1 protein kinase domain. ,subunit:Interacts with CSK/c-Src , ABL1 , RET and TGFB1I1. ,tissue specificity:Widely expressed with a maximal expression in lung and kidney. ,

Cytoplasm , cytoskeleton , cilium basal body . Cell junction , tight junction . Cytoplasm , cytoskeleton , microtubule organizing center , centrosome , centriole . Cytoplasmic vesicle , autophagosome . Golgi apparatus . Nucleus . Cytoplasm . Cytoplasm , cytoskeleton , spindle . Co-localizes to the cytoplasm only in presence of ESRRA (PubMed:21190936) . Translocates to the nucleus upon activation (PubMed:20638370) . At prometaphase I , metaphase I (MI) , anaphase I , telophase I , and metaphase II (MII) stages , is stably detected at the spindle (By similarity) . .

>>IL-17 signaling pathway